12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Glembatumumab vedotin: Final Phase IIb data

Final data from the open-label, U.S. Phase IIb EMERGE trial in 122 breast cancer patients with >=5% of their tumor cells expressing GPNMB showed that CDX-011 non-significantly improved median OS (7.5 vs. 7.4 months, p=0.24) and PFS (2.1 vs. 2 months, p=0.38) vs. single agent chemotherapy of the investigator's choosing. CDX-011 led to an ORR of 16% vs. 14% for chemotherapy and a DCR of 57% vs. 53% for chemotherapy. Celldex said the trial was not powered to detect statistical significance. In patients with high GPNMB expression, CDX-011 led to a median OS of 10 months...

Read the full 458 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >